Halda Therapeutics Raises $126M for Cancer Therapies in Series B Extension Funding

Halda Therapeutics secures $126 million in funding to advance RIPTAC candidates into clinical trials and expand its team.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here